CliffBio
biologic

Humira

adalimumab

Loss of exclusivityDecember 2014projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameHumira
Active ingredientadalimumab
Strength40MG/0.8ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalDecember 2002
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Humira patent cliff — loss of exclusivity December 2014 | CliffBio